PTO- 1478 |
Approved for use through 10/31/2024. OMB 0651-0009 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |
Serial Number: 98101694 |
Filing Date: 07/25/2023 |
Input Field |
Entered |
SERIAL NUMBER | 98101694 |
---|---|
MARK INFORMATION | |
*MARK | \\TICRS\EXPORT18\IMAGEOUT 18\981\016\98101694\xml1 \ APP0002.JPG |
SPECIAL FORM | YES |
USPTO-GENERATED IMAGE | NO |
COLOR MARK | NO |
*DESCRIPTION OF THE MARK (and Color Location, if applicable) |
The mark consists of three diagonal circles decreasing in size towards the center of an arc. |
PIXEL COUNT ACCEPTABLE | YES |
PIXEL COUNT | 380 x 387 |
REGISTER | Principal |
APPLICANT INFORMATION | |
*OWNER OF MARK | Crossbow Therapeutics, Inc. |
*MAILING ADDRESS | 1030 Massachusetts Avenue, Suite 210 |
*CITY | Cambridge |
*STATE (Required for U.S. applicants) |
Massachusetts |
*COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | United States |
*ZIP/POSTAL CODE (Required for U.S. and certain international addresses) |
02138 |
*EMAIL ADDRESS | XXXX |
LEGAL ENTITY INFORMATION | |
TYPE | corporation |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY OF INCORPORATION | Delaware |
GOODS AND/OR SERVICES AND BASIS INFORMATION | |
INTERNATIONAL CLASS | 042 |
*IDENTIFICATION | Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; Medical and scientific research in the field of cancer treatment and diagnosis; Medical and scientific research in the field of diagnosis and treatment of cancer and immunological diseases; Medical and scientific research information in the field of cancer and immunological diseases; Pharmaceutical research and development; Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Research and development in the field of cancer and immunological diseases; Scientific research for medical purposes in the area of cancerous diseases; Scientific research for medical purposes in the field of cancer and immunological diseases; Providing medical and scientific research information in the field of clinical trials; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Testing, inspection, research, or development of pharmaceutical preparations for gene therapy |
FILING BASIS | SECTION 1(b) |
ATTORNEY INFORMATION | |
NAME | Vincent J. Badolato |
ATTORNEY DOCKET NUMBER | 37870/19 |
ATTORNEY BAR MEMBERSHIP NUMBER | XXX |
YEAR OF ADMISSION | XXXX |
U.S. STATE/ COMMONWEALTH/ TERRITORY | XX |
FIRM NAME | Brown Rudnick LLP |
STREET | 601 Thirteenth Street NW, Suite 600 |
CITY | Washington |
STATE | District of Columbia |
COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | United States |
ZIP/POSTAL CODE | 20005 |
PHONE | 202-536-1758 |
FAX | 617.289.0809 |
EMAIL ADDRESS | trademarks@brownrudnick.com |
OTHER APPOINTED ATTORNEY | Peter J. Willsey, Daniel J. Healy, Katherine C. Dearing, Jason M. Sobel, Ian G. DiBernardo, Scott M. Smedresman, Merri C. Moken, Morgan Jones, Alvin B. Carter III and Stephanie P. Calnan |
CORRESPONDENCE INFORMATION | |
NAME | Vincent J. Badolato |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE | trademarks@brownrudnick.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) | vbadolato@brownrudnick.com; doakes@brownrudnick.com |
FEE INFORMATION | |
APPLICATION FILING OPTION | TEAS Standard |
NUMBER OF CLASSES | 1 |
APPLICATION FOR REGISTRATION PER CLASS | 350 |
*TOTAL FEES DUE | 350 |
*TOTAL FEES PAID | 350 |
SIGNATURE INFORMATION | |
SIGNATURE | /Geraldine Paulus/ |
SIGNATORY'S NAME | Geraldine Paulus |
SIGNATORY'S POSITION | Co-founder, VP of Corporate Development and Operations |
DATE SIGNED | 07/25/2023 |
SIGNATURE METHOD | Sent to third party for signature |
PTO- 1478 |
Approved for use through 10/31/2024. OMB 0651-0009 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |
Serial Number: 98101694 |
Filing Date: 07/25/2023 |
The applicant's current Correspondence Information: |
Vincent J. Badolato |
PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@brownrudnick.com SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): vbadolato@brownrudnick.com; doakes@brownrudnick.com Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS). |
|
|